S
Suresh Agarwal
Researcher at Duke University
Publications - 147
Citations - 5442
Suresh Agarwal is an academic researcher from Duke University. The author has contributed to research in topics: Venetoclax & Population. The author has an hindex of 34, co-authored 140 publications receiving 4205 citations. Previous affiliations of Suresh Agarwal include University of Minnesota & Boston University.
Papers
More filters
Journal ArticleDOI
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Courtney D. DiNardo,Keith W. Pratz,Anthony Letai,Brian A. Jonas,Andrew H. Wei,Michael J. Thirman,Martha Arellano,Mark G. Frattini,Hagop M. Kantarjian,Relja Popovic,Brenda Chyla,Tu Xu,Martin Dunbar,Suresh Agarwal,Rod A. Humerickhouse,Mack Mabry,Jalaja Potluri,Marina Konopleva,Daniel A. Pollyea +18 more
TL;DR: This combination phase 1b study enrolled previously untreated patients aged 65 years and over with acute myeloid leukaemia who were ineligible for standard induction therapy and suggested synergy between hypomethylating agents and venetoclax to determine the maximum tolerated dose and recommended phase 2 dose and analysed safety, pharmacokinetics, and anti-leukaemic activity in all patients.
Journal ArticleDOI
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H. Wei,Stephen A. Strickland,Jing Zhou Hou,Walter Fiedler,Tara L. Lin,Roland B. Walter,Roland B. Walter,Anoop K Enjeti,Anoop K Enjeti,Ing Soo Tiong,Michael R. Savona,Sangmin Lee,Brenda Chyla,Relja Popovic,Ahmed Salem,Suresh Agarwal,Tu Xu,Kaffa Fakouhi,Rod A. Humerickhouse,Wan Jen Hong,John Hayslip,Gail J. Roboz +21 more
TL;DR: Venetoclax plus LDAC has a manageable safety profile, producing rapid and durable remissions in older adults with AML ineligible for intensive chemotherapy, and high remission rate and low early mortality combined with rapid and Durable remission make venetoclAX and LDAC an attractive and novel treatment for older adults not suitable forintensive chemotherapy.
Journal ArticleDOI
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Shaji Kumar,Jonathan L. Kaufman,Cristina Gasparetto,Joseph R. Mikhael,Ravi Vij,Brigitte Pegourie,Lofti Benboubker,Thierry Facon,Martine Amiot,Philippe Moreau,Elizabeth Punnoose,Stefanie Alzate,Martin Dunbar,Tu Xu,Suresh Agarwal,Sari H. Enschede,Joel D. Leverson,Jeremy A. Ross,Paulo Maciag,Maria Verdugo,Cyrille Touzeau +20 more
TL;DR: Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile and evidence of single-agent antimyeloma activity in patients with relapsed/refractory MM, predominantly in patientswith t(11;14) abnormality and those with a favorable BCL2 family profile.
Journal ArticleDOI
Emergency general surgery: definition and estimated burden of disease.
Shahid Shafi,Michel B. Aboutanos,Suresh Agarwal,Carlos V.R. Brown,Marie Crandall,David V. Feliciano,Oscar D. Guillamondegui,Adil H. Haider,Kenji Inaba,Turner M. Osler,Steven E. Ross,Grace S. Rozycki,Gail T. Tominaga +12 more
TL;DR: The first list of ICD-9 diagnoses codes that define the scope of EGS based on current clinical practices is provided, with wide implications for EGS workforce training, access to care, and research.
Journal ArticleDOI
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour,John F. Seymour,Shuo Ma,Danielle M. Brander,Michael Y. Choi,Jacqueline C. Barrientos,Matthew S. Davids,Mary Ann Anderson,Mary Ann Anderson,Anne W. Beaven,Steven T. Rosen,Constantine S. Tam,Constantine S. Tam,Betty Prine,Suresh Agarwal,Wijith Munasinghe,Ming Zhu,Leanne Lash,Monali Desai,Elisa Cerri,Maria Verdugo,Su Young Kim,Rod A. Humerickhouse,Gary Gordon,Thomas J. Kipps,Andrew W. Roberts +25 more
TL;DR: The primary outcomes were to assess the safety profile, to determine the maximum tolerated dose, and to establish the recommended phase 2 dose of venetoclax when given in combination with rituximab.